04 Medium 6,901 2 Cigna CI 2 None 67.90 1.19 High 19,529 2 St Jude STJ 3 Wide 47.00 0.96 Medium 13,369 2 Vertex VRTX 3 None 79.49 0.89 High 17,961 2 Pioneer PXD 1 Narrow 142.25 1.50 Medium 19,943 1 Devon DVN 5 Narrow 58.79 0.59
Biotech names are weak today on the back of several ASCO data presentation releases: REGN -2.3% , ALXN -4.2% , VRTX -2.3% , CELG -4.5% , ARRY -2.2% , AMGN -1.4% . 1 comment!
By Northwest Trader : Cystic Fibrosis (CF) is caused by a defective gene that causes the body to produce thick, sticky mucus that clogs the lungs, promotes life threatening infections, causes diabetes, infertility, and hinders normal breakdown of nutrition and nutritional absorption. It is an evil
By John Fifield: As of late there has been a lot of chatter about how Vertex's ( VRTX ) stated intention to retire some debt into equity is bad for current shareholders. The chatter has been relentless by Vertex
By Life Sciences Report : In January 2013, The Life Sciences Report debuted its biotech Watchlist, which outlined ideas for investors keyed to catalysts in the drug development process that typically move biotechnology stocks. All stocks are affected by catalysts, but nowhere do they provide more
By Edward Vranic : The stock price of Vertex Pharmaceuticals ( VRTX ) spiked up 3% in early Wednesday trading after the ..... revenue and net earnings. However, by the end of the day VRTX gave up all but one penny of its gains to close at
By Tom Welch: Recently, shares of Catalyst Pharmaceutical Partners ( CPRX ) and Vertex Pharmaceuticals ( VRTX ) spiked dramatically upward, drawing the attention of many traders and investors. BioMarin ( BMRN ) has not been as dramatic
Vertex Pharmaceuticals Incorporated ( VRTX ) Q1 2013 Earnings Call April 30, 2013 5:00 pm ET Executives ..... http://seekingalpha.com/article/1387481- vertex - pharmaceuticals -incorporated-management-discusses-q1-2013-results-earnings-call-transcript
April 30 (Reuters) - Vertex Pharmaceuticals Inc on Tuesday increased by $20 million the 2013 forecast for sales of its cystic fibrosis drug Kalydeco, and said it anticipates seeking approval in 2014 of a CF combination therapy that has become a focus for investors.
More on Vertex Pharmaceuticals ( VRTX ): Q1 beats on both EPS and revenue, but net profit swung to a loss on a 25% drop in total sales as fewer patients initiated